The global asthma therapeutics market size reached USD 18.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.1 Billion by 2033
<p class="MsoNoSpacing" style="text-align: justify;"><span style="mso-bookmark: _Hlk168475565;"><span style="mso-bookmark: _Hlk168320012;"><span lang="EN-US" style="font-size: 12.0pt; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">IMARC Group, a leading market research company, has recently released a report titled “Asthma Therapeutics Market Report by Drug Class (Anti-Inflammatory Drugs, Bronchodilators, Combination Therapies), Product Type (Inhalers, Nebulizers), Treatment Type (Quick-Relief Medications, Long-Term Asthma Control Medications), Route of Administration (Inhalation, Oral, Parenteral), and Region 2025-2033”. The study provides a detailed analysis of the industry, including the global asthma therapeutics market share, trends, size, and industry trends forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.</span></span></span></p><p class="MsoNoSpacing" style="text-align: justify;"><span style="mso-bookmark: _Hlk168475565;"><span style="mso-bookmark: _Hlk168320012;"><span lang="EN-US" style="font-size: 12.0pt; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">The global </span></span></span><a href="https://www.imarcgroup.com/asthma-therapeutics-market"><span style="mso-bookmark: _Hlk168475565;"><span style="mso-bookmark: _Hlk168320012;"><span lang="EN-US" style="font-size: 12.0pt; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">asthma therapeutics market size</span></span></span></a><span style="mso-bookmark: _Hlk168475565;"><span style="mso-bookmark: _Hlk168320012;"><span lang="EN-US" style="font-size: 12.0pt; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;"> reached USD 18.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.1 Billion by 2033, exhibiting a growth rate (CAGR) of 1.8% during 2025-2033.</span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk168475565;"><span style="mso-bookmark: _Hlk168320012;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Request to Get the Sample Report:</span></strong></span></span></p><p class="MsoNormal"><a href="https://www.imarcgroup.com/asthma-therapeutics-market/requestsample"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">https://www.imarcgroup.com/asthma-therapeutics-market/requestsample</span></strong></a></p><p class="MsoNormal"><strong>Asthma Therapeutics Market Trends in 2025</strong></p><p class="MsoNormal">A notable trend in the asthma therapeutics market is the increasing emphasis on digital health solutions to support asthma management. As patients become more engaged in their health care, the demand for digital tools that assist in monitoring and managing asthma is expected to rise. By 2025, it is projected that mobile applications and wearable devices will play a significant role in helping patients track their symptoms, medication usage, and environmental triggers. These digital health solutions will provide personalized insights, allowing individuals to make informed decisions about their treatment and lifestyle choices.</p><p class="MsoNormal">Furthermore, the integration of telehealth services will enable patients to consult with healthcare professionals remotely, facilitating timely interventions and adjustments to treatment plans. This trend reflects a broader movement towards the digitization of healthcare, where technology enhances patient engagement and improves outcomes. As healthcare providers increasingly recognize the importance of patient education and self-management, the incorporation of digital health tools into asthma care will become a key component of therapeutic strategies, ultimately driving growth in the asthma therapeutics market.</p><p class="MsoNormal"><strong>Market Dynamics of the Asthma Therapeutics Market</strong></p><p class="MsoNormal"><strong>Increasing Prevalence of Asthma and Respiratory Disorders</strong></p><p class="MsoNormal">One of the primary dynamics driving the asthma therapeutics market is the increasing prevalence of asthma and other respiratory disorders globally. According to various health organizations, asthma rates have been on the rise, particularly in urban areas where pollution and allergens are more prevalent. By 2025, it is projected that the number of asthma patients will continue to grow, fueled by factors such as environmental changes, lifestyle shifts, and increased awareness of respiratory health. This surge in asthma cases is prompting healthcare providers and pharmaceutical companies to focus on developing more effective and targeted therapies. The growing patient population not only increases the demand for existing treatments but also encourages innovation in drug development, leading to the introduction of novel biologics and personalized medicine approaches.</p><p class="MsoNormal">Furthermore, the rising burden of asthma on healthcare systems is leading to increased funding for research and development, enabling the discovery of new therapeutic options. As a result, the asthma therapeutics market is poised for significant growth, driven by the urgent need to address the rising incidence of asthma and improve patient outcomes.</p><p class="MsoNormal"><strong>Advancements in Drug Delivery Systems</strong></p><p class="MsoNormal">Another crucial dynamic influencing the asthma therapeutics market is the advancements in drug delivery systems. Traditional inhalers, while effective, often face challenges related to patient adherence and proper usage techniques. By 2025, it is anticipated that innovative drug delivery technologies, such as smart inhalers and nebulizers, will gain traction in the market. These devices are designed to enhance patient experience by providing real-time feedback on medication usage, adherence tracking, and reminders for doses. Smart inhalers, equipped with connectivity features, allow patients to monitor their inhalation technique and receive alerts when their medication is running low. This technology not only empowers patients to manage their condition more effectively but also provides valuable data to healthcare providers for better treatment management.</p><p class="MsoNormal">Additionally, advancements in formulations, such as dry powder inhalers and soft mist inhalers, are improving drug delivery efficiency and minimizing side effects. The integration of these advanced delivery systems into asthma management strategies is expected to drive demand for therapeutics, as they enhance the overall effectiveness of treatment regimens and improve patient outcomes.</p><p class="MsoNormal"><strong>Growing Focus on Personalized Medicine</strong></p><p class="MsoNormal">The asthma therapeutics market is also witnessing a significant shift towards personalized medicine, which tailors’ treatment strategies to individual patient needs. This dynamic is gaining momentum as healthcare providers recognize that asthma is not a one-size-fits-all condition; it varies widely among patients in terms of triggers, severity, and response to treatment. By 2025, it is projected that the development of biomarker-driven therapies will become more prevalent, enabling clinicians to identify specific patient subgroups that may benefit from targeted treatments. The rise of biologics, which are designed to act on specific pathways involved in asthma pathophysiology, exemplifies this trend. These therapies offer significant benefits for patients with severe asthma who do not respond well to conventional treatments.</p><p class="MsoNormal">Furthermore, the integration of genomic data and advanced diagnostics into asthma management plans will facilitate more accurate treatment decisions. As the focus on personalized medicine continues to grow, pharmaceutical companies will likely invest in research to develop tailored therapies that address the unique characteristics of asthma in different patient populations, thereby enhancing treatment efficacy and improving quality of life.</p><p class="MsoNormal"><strong><u><span lang="EN-US" style="mso-ansi-language: EN-US;">Asthma Therapeutics Market Report Segmentation:</span></u></strong></p><p class="MsoNormal" style="text-align: justify;"><strong><u><span lang="EN-US" style="mso-ansi-language: EN-US;">By Drug Class:</span> </u></strong></p><p class="MsoListParagraphCxSpFirst" style="text-indent: -18.0pt; line-height: 107%; mso-list: l5 level1 lfo1;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Anti-Inflammatory Drugs</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l5 level1 lfo1;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Bronchodilators</span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l5 level1 lfo1;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Combination Therapies</span></p><p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="mso-ansi-language: EN-US;">Combination therapies represented the largest segment owing to their enhanced efficacy in controlling asthma symptoms by targeting multiple pathways simultaneously.</span> </p><p class="MsoNormal" style="text-align: justify;"><strong><u><span lang="EN-US" style="mso-ansi-language: EN-US;">By Product Type:</span> </u></strong></p><p class="MsoListParagraphCxSpFirst" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Inhalers</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Dry Powder Inhalers</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Metered Dose Inhalers</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Soft Mist Inhalers</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Nebulizers</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Pneumatic Nebulizers</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Ultrasonic Nebulizers</span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l3 level1 lfo2;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Mesh Nebulizers</span></p><p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="mso-ansi-language: EN-US;">Inhalers accounted for the largest market share due to their ease of use, rapid symptom relief, and direct delivery of medication to the lungs. </span> </p><p class="MsoNormal" style="text-align: justify;"><strong><u><span lang="EN-US" style="mso-ansi-language: EN-US;">By Treatment Type:</span> </u></strong></p><p class="MsoListParagraphCxSpFirst" style="text-indent: -18.0pt; line-height: 107%; mso-list: l2 level1 lfo3;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Quick-Relief Medications</span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l2 level1 lfo3;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Long-Term Asthma Control Medications</span></p><p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="mso-ansi-language: EN-US;">Long-term asthma control medications represented the largest segment as they are essential for managing chronic asthma and preventing frequent exacerbations. </span> </p><p class="MsoNormal" style="text-align: justify;"><strong><u><span lang="EN-US" style="mso-ansi-language: EN-US;">By Route of Administration:</span> </u></strong></p><p class="MsoListParagraphCxSpFirst" style="text-indent: -18.0pt; line-height: 107%; mso-list: l6 level1 lfo4;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Inhalation</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l6 level1 lfo4;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Oral</span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l6 level1 lfo4;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-fareast-language: EN-IN;">Parenteral</span></p><p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="mso-ansi-language: EN-US;">Inhalation</span> <span lang="EN-US" style="mso-ansi-language: EN-US;">constituted the largest segment as it is the most effective route for asthma treatment, delivering medication directly to the airways with minimal systemic side effects.</span> </p><p class="MsoNormal" style="text-align: justify;"><strong><u><span lang="EN-US" style="mso-ansi-language: EN-US;">Regional Insights:</span> </u></strong></p><p class="MsoNormal" style="text-align: justify;"><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span><span style="color: black; mso-color-alt: windowtext; background: white; mso-fareast-language: EN-IN;">North America</span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l0 level1 lfo5;"><span style="mso-bookmark: _Hlk174113088;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; background: white; mso-fareast-language: EN-IN;">Asia-Pacific</span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l0 level1 lfo5;"><span style="mso-bookmark: _Hlk174113088;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; background: white;">Europe </span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l0 level1 lfo5;"><span style="mso-bookmark: _Hlk174113088;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; background: white; mso-fareast-language: EN-IN;">Latin America</span></span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l0 level1 lfo5;"><span style="mso-bookmark: _Hlk174113088;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; mso-fareast-language: EN-IN;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="color: black; mso-color-alt: windowtext; background: white;">Middle East and Africa</span></span></p><p class="MsoNormal" style="text-align: justify;"><span lang="EN-US" style="mso-ansi-language: EN-US;">North America's dominance in the asthma therapeutics market is attributed to its advanced healthcare infrastructure, high prevalence of asthma, and widespread adoption of innovative therapies. </span>patient engagement and real-time management of asthma is enhancing the market growth.</p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk169080876;"><span style="mso-bookmark: _Hlk169532802;"><span style="mso-bookmark: _Hlk170203962;"><span style="mso-bookmark: _Hlk174113100;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Competitive Landscape with Key Players:</span></strong></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk169261741;"><span style="mso-bookmark: _Hlk169080876;"><span style="mso-bookmark: _Hlk169532802;"><span style="mso-bookmark: _Hlk170203962;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">The competitive landscape of the asthma therapeutics market size has been studied in the report with the detailed profiles of the key players operating in the market.</span></span></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk169532802;"><span style="mso-bookmark: _Hlk170203962;"><span style="mso-bookmark: _Hlk174113100;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Some of These Key Players Include</span></strong></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;"><span style="font: 7.0pt 'Times New Roman';"> </span></span></span>AstraZeneca PLC</span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Abbott Laboratories </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Amgen Inc. </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Biogen Inc. </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Boehringer Ingelheim International GmbH </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->F. Hoffmann-La Roche Ltd. </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->GlaxoSmithKline Plc </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Merck Sharp & Dohme Corp. </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Novartis International AG </span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Sunovion Pharmaceuticals Inc </span></span></span></span></span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l1 level1 lfo7;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol; color: #111111; mso-bidi-font-weight: bold;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]-->Teva Pharmaceutical Industries Ltd.</span></span></span></span></span><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: #111111; background: white;"> </span></strong></span></span></span></span></span><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><strong style="mso-bidi-font-weight: normal;"><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: #111111; background: white; mso-no-proof: yes;"><!--[endif]--></span></strong></span></span></span></span></span></p><p class="MsoNormal"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: #111111; background: white;">Ask Analyst for Customized Report:</span></strong></span></span></span></span></span></p><p class="MsoNormal"><a href="https://www.imarcgroup.com/request?type=report&id=2338&flag=C"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk170229698;"><span style="mso-bookmark: _Hlk168475505;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; background: white;">https://www.imarcgroup.com/request?type=report&id=2338&flag=C</span></strong></span></span></span></span></span></a></p><p class="MsoNormal"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><a name="_Hlk170229712"></a><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Key Highlights of the Report:</span></strong></span></span></span></p><p class="MsoListParagraphCxSpFirst" style="text-indent: -18.0pt; line-height: 107%; mso-list: l4 level1 lfo6;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Market Performance (2018-2023)</span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l4 level1 lfo6;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Market Outlook (2024-2032)</span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l4 level1 lfo6;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Market Trends</span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l4 level1 lfo6;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Market Drivers and Success Factors</span></span></span></span></span></p><p class="MsoListParagraphCxSpMiddle" style="text-indent: -18.0pt; line-height: 107%; mso-list: l4 level1 lfo6;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Impact of COVID-19</span></span></span></span></span></p><p class="MsoListParagraphCxSpLast" style="text-indent: -18.0pt; line-height: 107%; mso-list: l4 level1 lfo6;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><!-- [if !supportLists]--><span style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><span style="mso-list: Ignore;">·<span style="font: 7.0pt 'Times New Roman';"> </span></span></span><!--[endif]--><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">Value Chain Analysis</span></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.</span></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><strong><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">About Us</span></strong></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.</span></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin;">IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.</span></span></span></span></span></p><p class="MsoNormal" style="line-height: normal; margin: 12.0pt 0cm 12.0pt 0cm;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><strong><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">Contact Us:</span></strong></span></span></span></span></p><p class="MsoNormal" style="line-height: normal; margin: 12.0pt 0cm 12.0pt 0cm;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">IMARC Group</span></span></span></span></span></p><p class="MsoNormal" style="line-height: normal; margin: 12.0pt 0cm 12.0pt 0cm;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">134 N 4th St</span></span></span></span></span></p><p class="MsoNormal" style="line-height: normal; margin: 12.0pt 0cm 12.0pt 0cm;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">Brooklyn, NY 11249, USA</span></span></span></span></span></p><p class="MsoNormal" style="line-height: normal; margin: 12.0pt 0cm 12.0pt 0cm;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">Website: </span></span></span></span></span><a href="imarcgroup.com"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">imarcgroup.com</span></span></span></span></span></a></p><p class="MsoNormal" style="line-height: normal; margin: 12.0pt 0cm 12.0pt 0cm;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">Email: sales@imarcgroup.com</span></span></span></span></span></p><p class="MsoNormal" style="text-align: justify;"><span style="mso-bookmark: _Hlk174113100;"><span style="mso-bookmark: _Hlk169259821;"><span style="mso-bookmark: _Hlk169081013;"><span style="mso-bookmark: _Hlk170229712;"><span style="mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: Aptos; mso-bidi-theme-font: minor-latin; color: black; mso-font-kerning: 0pt; mso-ligatures: none; mso-fareast-language: EN-IN;">Americas: +1-631-791-1145 | Europe & Africa: +44-753-713-2163 | Asia: +91-120-433-0800</span></span></span></span></span></p>
Comments
0 comment